Abstract
CI-994, a substituted benzamide derivative, is a compound that showed solid tumor selectivity for a variety of solid tumor models compared to L1210 leukemia. Due to its lack of aqueous solubility, it requires oral administration. Female B6D2F1 mice were treated with CI-994 once daily by oral administration of 50 mg/kg for 14 days. Following treatment mice were evaluated for pharmacodynamic effects as well as the pharmacokinetic behavior of CI-994 and the de-acetylated derivative dinaline. Mice samples (plasma, urine, feces) were analyzed using solid phase extraction, reverse phase HPLC and ultraviolet detection. The plasma distribution and elimination half-lives for CI-994 were 51 minutes and 9.4 hours, respectively, on D-1; 31 minutes and 3.4 hours, respectively on D-14. The apparent plasma distribution and elimination half-lives for dinaline were 27 minutes and 2.4 hours, respectively, on D-1; 40 minutes and 7.3 hours, respectively on D-14. The CI-994 AUC on D-1 and D-14 were 2879 and 2407 µ × minutes, respectively; while the dinaline AUC on D-1 and D-14 were 87 and 92 µg/ml × minutes, respectively. Urinary excretion for CI-994 and dinaline was higher on D-14, while the fecal excretion was the same on both days. The Colon #38 tumor growth in treated mice was reduced to 22% of that observed in the controls by D-19. The levels of all blood cells were reduced in the treated mice when compared to controls and the total WBC was the most affected (median 38%). Recovery to pretreatment levels occurred quickly following treatment cessation. Phase I evaluation of chronic oral administration of CI-994 is currently ongoing.
Similar content being viewed by others
References
Alberts DS, Chang SY, Chen HSG, Evans TL, Moon TE: Oral melphalan kinetics. Clin Pharmacol Ther 26: 737–745, 1979.
D'Incalci M, Bolis G, Mangioni C, Morasca L, Garattini S: Variable oral absorption of hexamethylamine in man. Cancer Treat Rep 62: 2117–2119, 1978.
Steward DJ, Nundy D, Marsun J, Tetreault L, Prior J: Bioavailability pharmacokinetics and clinical effects of an oral preparation of etoposide. Cancer Treat Rep 69: 269–273, 1985.
Corbett T, Valeriote F, LoRusso P, Polin L, Panchapor C, Pugh S, White K, Knight J, Demchik L, Jones J, Jones L, Lowichik N, Biernat L, Foster B, Wozniak A, Lisow L, Valdivieso M, Baker L, Leopold W, Sebolt J, Bissery MC, Mattes K, Dzubow J, Rake J, Perni R, Wentland M, Coughlin S, Show JM, Liversidge G, Liversidge E, Bruno J, Sarpotdar P, Moore R, Patterson G: Tumor models and the discovery and secondary evaluation of solid tumor active agents. Int J Pharmacognosy 33(supplement): 102–122, 1995.
Lelieveld P, Middeldorp RJF, van Putten LM: Effectiveness of p-aminobenzoyl-o-phenylenediamine (GOE 1734) against mouse, rat and human tumour cells. Cancer Chemother Pharmacol 15: 88–90, 1985.
Leopold WR, Hook KE, Fry DW: Activity and biochemical properties of GOE 1734 (PD 104208), and anticancer agent with a novel mechanism of activity (Abstract). Proc AACR 28: 302, 1987.
Jennrich RI, Sampson PF: Application of stepwise repression to non-linear least squares estimation. Techometrics 10: 63–72, 1968.
Ottaway JH: Normalization in the fitting of data by iterative methods. Biochem J 134: 729–736, 1973.
Wagner JG: Fundamentals of Clinical Pharmacokinetics. Drug Intelligence Publications, Chicago, 1975, p 38.
Corbett TH, Griswold DP Jr, Roberts BJ, Peckham JC, Schabel FM Jr: Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 35: 2434–2439, 1975.
Venditti JM: Preclinical drug evaluations: rationale and methods. Semin Oncol 8: 349–361, 1981.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Foster, B.J., Jones, L., Wiegand, R. et al. Preclinical pharmacokinetic, antitumor and toxicity studies with CL-994 (N-acetyldinaline). Invest New Drugs 15, 187–194 (1997). https://doi.org/10.1023/A:1005846026398
Issue Date:
DOI: https://doi.org/10.1023/A:1005846026398